2018 Biotechnology Awards

8 GHP / Biotechnology Awards 2018 , Truffle Capital, an independent venture capital firm focused on setting up and financing start-ups with disruptive technologies in life sciences and information technology, has announced the initial closing of its new institutional venture fund - Truffle BioMedTech - at $102 million (€85 million). European and Asian institutional and corporate investors, as well as family offices, invested in this initial closing. Based on other investments in discussion or already confirmed, Truffle is confident that it will meet its $240 million target for this BioMedTech fund in 2018. “As a major European venture capital player in the fields of interventional medicine, GHB17002 Truffle Capital Announces The First Closing Of Its New BioMedTech Venture Fund Dedicated To Medical Devices And Biotechnology Truffle identifies radical innovations at top universities inNorthAmerica and Europe, to set up start-ups in Francewith the potential to become global leaders. connected bioprostheses and biotechnology, Truffle Capital attracts prominent investors, scientists, engineers, clinicians and entrepreneurs who share its vision,” says Philippe Pouletty, MD, co-founder and CEO of Truffle Capital. “Truffle’s entrepreneur-investor business model works well, as demonstrated by the recent successes of Vexim, Carmat, Symetis, Pharnext, Carbios and Abivax, all founded or co-founded by Truffle Capital, alongside world-class management and research teams. After selecting major breakthroughs from top universities in North America and Europe, Truffle BioMedTech will create start- ups in France, each with the potential to become a global leader thanks to a disruptive and life-changing medical device, drug or healthcare product. For each start-up, Truffle Capital sets up an ambitious R&D team, an experienced management team, and attracts co-investors to promote growth to advanced clinical, manufacturing and commercial stages.” Truffle Capital’s life sciences management team has long operational and investment experience: previous Truffle Capital funds have founded or co-founded and financed 20 medtech and biotech companies (10 of which have been listed on stock markets and 3 of which have been acquired by corporate partners). Close to 100,000 patients have already been treated using products developed by Truffle portfolio companies, which would not have existed without Truffle Capital. Immediately following the fund’s first closing, Truffle Capital set up and financed three companies in France: HoliStick Medical, chaired by Antoine Pau, Truffle Partner; ArteDrone, chaired by Alain Chevallier, Truffle Partner; and Nanosive, chaired by Philippe Pouletty. In total, a dozen companies are expected to be financed by the new fund. In addition to the initial closing and investments of the BioMedTech fund, Truffle Capital has also completed the initial closing of its Truffle Financial Innovation Fund dedicated to FinTechs and InsurTechs, and has been selected to manage a dedicated fund for the FRR (Fonds de réserves pour les retraites), one of the largest French pension funds. Patrick Kron, Chairman, and Philippe Pouletty and Bernard- Louis Roques, CEOs of Truffle Capital, said, “Sticking to our successful entrepreneur/investor business model, we are now focusing our fundraising on institutional investors, corporates and family offices, while maintaining our funds dedicated to retail investors that benefit from tax incentives.” Truffle Capital Announces The First Closing Of Its New BioMedTech Venture Fund Dedicated To Medical Devices And Biotechnology